Modulating PRMT5 activity with selective PRMT5 inhibitors preferentially suppresses inflammatory Th1 vs. Th2 cell proliferation and EAE, indicating that PRMT5 may be a therapeutic target in MS (10). The gene discussed is PRMT5; the disease is myeloid sarcoma.